Should a patient who has completed one year of dual antiplatelet therapy (prasugrel and aspirin), quit smoking, and has an LDL cholesterol of 60 mg/dL on a statin plus ezetimibe, remain on dual therapy or continue aspirin alone?

Recommendation: Discontinue Prasugrel and Continue Aspirin Monotherapy

After completing 12 months of DAPT following ACS, this patient should transition to aspirin monotherapy alone. The patient has successfully completed the guideline-recommended duration of dual antiplatelet therapy and does not meet criteria for extended DAPT continuation.

Rationale Based on Guidelines

The 2017 ESC guidelines 1 and 2016 ACC/AHA guidelines 2 provide clear Class I recommendations that DAPT with a P2Y12 inhibitor on top of aspirin is recommended for 12 months in ACS patients unless contraindications such as excessive bleeding risk exist. Your patient has completed this standard duration.

Key Decision Points Against Continuing DAPT:

Bleeding Risk Considerations:

• The guidelines specify that continuation beyond 12 months is only Class IIb (may be reasonable) in patients who have tolerated DAPT without bleeding complications AND are not at high bleeding risk 2
• This is a discretionary recommendation, not a mandate
• The patient is asymptomatic with excellent risk factor control

Risk Factor Optimization Achieved:

• Smoking cessation completed
• LDL-C at 60 mg/dL on statin + ezetimibe (well below the <70 mg/dL target, approaching the <55 mg/dL very high-risk target)
• This aggressive lipid management significantly reduces residual ischemic risk 3, 4

The Evidence on Extended DAPT

The 2016 ACC/AHA guideline 2 states that extended DAPT beyond 12 months in ACS patients is Class IIb (may be reasonable), meaning the benefit-to-risk ratio is less certain. The ESC guidelines 1 similarly note that 12 months is the standard recommendation unless bleeding risk is excessive (in which case shorter duration may be considered).

Critical nuance: Extended DAPT studies have shown ischemic benefit but at the cost of increased bleeding risk 5. The decision requires balancing:

• Thrombotic risk (reduced by excellent lipid control and smoking cessation)
• Bleeding risk (increases with prolonged therapy)

Practical Algorithm for This Patient

Stop prasugrel after 12 months and continue aspirin 75-100 mg daily because:

1. Standard duration completed: 12 months of DAPT is the Class I recommendation 1

2. No high-risk features requiring extension:

   • Not undergoing repeat PCI
   • No recurrent ischemic events
   • Asymptomatic status
   • Excellent secondary prevention (smoking cessation, optimal LDL-C)

3. Aspirin continuation is Class I: Aspirin 75-100 mg daily should be continued indefinitely in patients with coronary artery disease 2, 1

Important Caveats

If any of the following were present, reconsider extended DAPT:

• Recurrent ischemic symptoms
• Complex coronary anatomy (left main disease, multivessel disease with incomplete revascularization)
• Prior stent thrombosis
• Diabetes with additional high-risk features
• Chronic kidney disease

Bleeding risk assessment: The PRECISE-DAPT score can help quantify bleeding risk if there's uncertainty, though it's not required for routine decision-making 1.

Monitor for: Any new ischemic symptoms that might warrant reintroduction of DAPT, though this is uncommon in well-controlled patients.

Lipid Management Continuation

Continue current statin + ezetimibe regimen. The patient's LDL-C of 60 mg/dL represents excellent control 3, 4, 6. This aggressive lipid-lowering provides substantial ongoing cardiovascular protection and reduces the incremental benefit that might be gained from extended DAPT.